SBMF.F Stock Overview
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 2/6 |
Past Performance | 1/6 |
Financial Health | 5/6 |
Dividends | 3/6 |
Sino Biopharmaceutical Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | HK$0.38 |
52 Week High | HK$0.54 |
52 Week Low | HK$0.32 |
Beta | 0.52 |
1 Month Change | 5.63% |
3 Month Change | n/a |
1 Year Change | -31.64% |
3 Year Change | -62.10% |
5 Year Change | -59.71% |
Change since IPO | 3.46% |
Recent News & Updates
Recent updates
Shareholder Returns
SBMF.F | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | 4.6% | -2.2% | -3.7% |
1Y | -31.6% | 11.6% | 20.5% |
Return vs Industry: SBMF.F underperformed the US Pharmaceuticals industry which returned 11.7% over the past year.
Return vs Market: SBMF.F underperformed the US Market which returned 20.2% over the past year.
Price Volatility
SBMF.F volatility | |
---|---|
SBMF.F Average Weekly Movement | n/a |
Pharmaceuticals Industry Average Movement | 9.6% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.4% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SBMF.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine SBMF.F's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2000 | 25,806 | Eric S. Y. Tse | www.sinobiopharm.com |
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines comprising Qingkeshu tablets, Focus V capsules, Annike injection, and Anyue capsules; liver disease medicines, including Tianqing ganmei injection and Runzhong dispersible tablets; and respiratory system medicines, such as Tianqing suchang suspension for inhalation and Tianyun for injection.
Sino Biopharmaceutical Limited Fundamentals Summary
SBMF.F fundamental statistics | |
---|---|
Market cap | US$5.76b |
Earnings (TTM) | US$255.17m |
Revenue (TTM) | US$3.62b |
22.6x
P/E Ratio1.6x
P/S RatioIs SBMF.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
SBMF.F income statement (TTM) | |
---|---|
Revenue | CN¥26.20b |
Cost of Revenue | CN¥4.99b |
Gross Profit | CN¥21.21b |
Other Expenses | CN¥19.36b |
Earnings | CN¥1.85b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 0.10 |
Gross Margin | 80.95% |
Net Profit Margin | 7.05% |
Debt/Equity Ratio | 32.0% |
How did SBMF.F perform over the long term?
See historical performance and comparison